REPLIGEN CORP (RGEN) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 64.61M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | 364.90M USD | Cost of Goods and Services Sold |
| Research and development | 56.97M USD | Research and Development Expense |
| Selling, general and administration | 302.05M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $64.61M | (m) | $364.90M | $56.97M | $302.05M | (m) |
| 2026-03-31 | $64.53M | (m) | $360.18M | $56.52M | $296.34M | (m) |
| 2025-12-31 | $55.17M | (m) | $352.01M | $54.18M | $290.51M | (m) |
| 2025-09-30 | $798.00K | (m) | $386.63M | $52.73M | $276.62M | (m) |
| 2025-06-30 | $-23.86M | (m) | $375.73M | $48.27M | $278.57M | (m) |
| 2025-03-31 | $-32.29M | (m) | $361.82M | $44.89M | $272.82M | (m) |
| 2024-12-31 | $-35.11M | (m) | $359.79M | $43.20M | $263.37M | (m) |
| 2024-09-30 | $11.26M | (m) | $319.22M | $41.81M | $260.52M | (m) |
| 2024-06-30 | $7.44M | (m) | $346.48M | $42.67M | $239.36M | (m) |
| 2024-03-31 | $25.35M | (m) | $348.47M | $41.81M | $223.63M | (m) |
| 2023-12-31 | $54.58M | (m) | $353.92M | $42.72M | $218.11M | (m) |
| 2023-09-30 | $104.30M | (m) | $356.49M | $43.55M | $213.84M | (m) |
| 2023-06-30 | $152.16M | (m) | $338.37M | $43.20M | $212.02M | (m) |
| 2023-03-31 | $195.93M | (m) | $345.32M | $43.94M | $217.70M | (m) |
| 2022-12-31 | $224.67M | (m) | $345.83M | $43.94M | $215.83M | (m) |
| 2022-09-30 | $213.26M | (m) | $337.18M | $41.94M | $214.65M | (m) |
| 2022-06-30 | $205.79M | (m) | $326.16M | $40.87M | $209.38M | (m) |
| 2022-03-31 | $190.87M | (m) | $301.89M | $38.82M | $199.07M | (m) |
| 2021-12-31 | $167.25M | (m) | $279.28M | $34.27M | $183.87M | (m) |
| 2021-09-30 | $147.24M | (m) | $245.40M | $31.88M | $168.15M | (m) |
| 2021-06-30 | $123.00M | (m) | $209.53M | $27.14M | $148.83M | (m) |
| 2021-03-31 | $94.30M | (m) | $184.40M | $23.09M | $131.22M | (m) |
| 2020-12-31 | $69.82M | (m) | $156.63M | $20.18M | $119.62M | (m) |
| 2020-09-30 | $58.30M | (m) | $138.59M | $18.63M | $111.56M | (m) |
| 2020-06-30 | $45.30M | (m) | $130.39M | $19.64M | $107.14M | (m) |
| 2020-03-31 | $36.82M | (m) | $124.24M | $20.53M | $104.11M | (m) |
| 2019-12-31 | $36.08M | (m) | $119.10M | $19.45M | $95.61M | (m) |
| 2019-09-30 | $38.04M | (m) | $112.57M | $17.43M | $84.67M | (m) |
| 2019-06-30 | $37.96M | (m) | $103.33M | $15.60M | $75.90M | (m) |
| 2019-03-31 | $31.18M | (m) | $93.71M | $16.15M | $68.79M | (m) |
| 2018-12-31 | $25.99M | (m) | $86.53M | $15.82M | $65.69M | (m) |
| 2018-09-30 | $21.40M | (m) | (m) | $15.74M | $64.49M | (m) |
| 2018-06-30 | $13.10M | (m) | (m) | $14.14M | $63.63M | (m) |
| 2018-03-31 | $14.30M | $155.48M | (m) | $10.22M | $58.23M | 9.20% |
| 2017-12-31 | $14.01M | $141.24M | (m) | $8.67M | $51.51M | 9.92% |
| 2017-09-30 | $13.65M | $125.22M | (m) | $7.64M | $43.93M | 10.90% |
| 2017-06-30 | $17.80M | $113.32M | (m) | $7.53M | $36.06M | 15.71% |
| 2017-03-31 | $18.19M | $110.04M | (m) | $7.56M | $33.02M | 16.53% |
| 2016-12-31 | $15.97M | $104.54M | (m) | $7.36M | $30.85M | 15.28% |
| 2016-09-30 | $14.50M | (m) | (m) | $6.75M | $28.76M | (m) |
| 2016-06-30 | $14.44M | (m) | (m) | $6.35M | $27.59M | (m) |
| 2016-03-31 | $13.19M | (m) | (m) | $5.71M | $25.69M | (m) |
| 2015-12-31 | $13.76M | $83.54M | (m) | $5.74M | $24.70M | 16.48% |
| 2015-09-30 | $12.40M | $78.48M | (m) | $5.64M | $23.20M | 15.80% |
| 2015-06-30 | $10.92M | $73.94M | (m) | $5.80M | $21.71M | 14.77% |
| 2015-03-31 | $9.42M | $68.04M | (m) | $5.98M | $19.80M | 13.85% |
| 2014-12-31 | $10.69M | $63.55M | (m) | $5.61M | $17.15M | 16.82% |
| 2014-09-30 | $15.81M | $62.54M | (m) | $5.70M | $15.55M | 25.29% |
| 2014-06-30 | $21.64M | $66.08M | (m) | $5.48M | $13.98M | 32.75% |
| 2014-03-31 | $24.64M | $68.04M | (m) | $6.36M | $12.78M | 36.21% |
| 2013-12-31 | $22.87M | $68.17M | (m) | $7.34M | $12.70M | 33.55% |
| 2013-09-30 | $24.10M | $71.60M | (m) | $8.26M | $12.59M | 33.66% |
| 2013-06-30 | $18.25M | $67.88M | (m) | $9.27M | $12.81M | 26.88% |
| 2013-03-31 | $13.46M | $65.90M | (m) | $9.86M | $13.11M | 20.43% |
| 2012-12-31 | $11.08M | $62.27M | (m) | $10.49M | $13.23M | 17.80% |
| 2012-09-30 | $3.13M | $50.62M | (m) | $11.02M | $14.49M | 6.19% |
| 2012-06-30 | $1.50M | $44.14M | (m) | $11.66M | $13.85M | 3.40% |
| 2012-03-31 | $60.01K | $36.27M | (m) | $12.27M | $12.73M | 0.17% |
| 2011-12-31 | $-3.19M | $29.36M | (m) | $13.25M | $11.49M | -10.88% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $-374.07K | $27.29M | (m) | $12.53M | $8.02M | -1.37% |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $-5.77M | $20.97M | (m) | $14.16M | $7.07M | -27.50% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |